Mechanistic insights on the inhibition of C5 DNA methyltransferases by zebularine

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  Champion, Christine ^a,b   Guianvarc'h, Dominique ^c   Sénamaud Beaufort, Catherine ^a,b   Jurkowska, Renata Z ^d   Jeltsch, Albert ^d   Ponger, Loïc ^a,b   Arimondo, Paola B ^a,b   Guieysse Peugeot, Anne Laure ^a,b  

^a MUSÉUM NATIONAL D'HISTOIRE NATURELLE   (France)

^b INSERM   (France)

^c Centre National de la Recherche Scientifique   (France)

^d JACOBS UNIVERSITY BREMEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DEOXYCYTIDINE; DNA METHYLTRANSFERASE; FLUCYTOSINE DEOXYRIBOSIDE; ZEBULARINE; CYTIDINE; DNA; DNA (CYTOSINE 5) METHYLTRANSFERASE; DRUG DERIVATIVE; ENZYME INHIBITOR; PYRIMIDIN 2 ONE BETA RIBOFURANOSIDE; PYRIMIDIN-2-ONE BETA-RIBOFURANOSIDE;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; COVALENT BOND; DEMETHYLATION; DNA CROSS LINKING; DNA METHYLATION; DRUG DNA BINDING; DRUG MECHANISM; DRUG STABILITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; GENE EXPRESSION REGULATION; INCUBATION TIME; POLYACRYLAMIDE GEL ELECTROPHORESIS; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; METHYLATION; MOUSE; NUCLEOTIDE SEQUENCE;

MAMMALIA;

ANIMALS; AZACITIDINE; BASE SEQUENCE; CYTIDINE; DNA; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; ENZYME INHIBITORS; HUMANS; METHYLATION; MICE;

EID: 77957878987     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012388     Document Type: Article

References (56)

1. Laird PW (2005) Cancer epigenetics. Hum Mol Genet 14 Spec No 1: R65-76.
2. Ehrlich M (2002) DNA methylation in cancer: too much, but also too little. Oncogene 21: 5400-5413.
3. Robertson KD, Jones PA (2000) DNA methylation: past, present and future directions. Carcinogenesis 21: 461-467.
4. Jeltsch A (2006) Molecular enzymology of mammalian DNA methyltransferases. Curr Top Microbiol Immunol 301: 203-225.
5. Clark J, Shevchuk T, Kho MR, Smith SS (2003) Methods for the design and analysis of oligodeoxynucleotide-based DNA (cytosine-5) methyltransferase inhibitors. Anal Biochem 321: 50-64.
6. Hermann A, Gowher H, Jeltsch A (2004) Biochemistry and biology of mammalian DNA methyltransferases. Cell Mol Life Sci 61: 2571-2587.
7. Yoo CB, Jones PA (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5: 37-50.
8. Gore SD, Jones C, Kirkpatrick P (2006) Decitabine. Nat Rev Drug Discov 5: 891-892.
9. Issa JP, Kantarjian HM, Kirkpatrick P (2005) Azacitidine. Nat Rev Drug Discov 4: 275-276.
10. Santi DV, Norment A, Garrett CE (1984) Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci U S A 81: 6993-6997.
11. Gabbara S, Bhagwat AS (1995) The mechanism of inhibition of DNA (cytosine- 5-)-methyltransferases by 5-azacytosine is likely to involve methyl transfer to the inhibitor. Biochem J 307(Pt 1): 87-92.
12. Creusot F, Acs G, Christman JK (1982) Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine. J Biol Chem 257: 2041-2048.
13. Taylor SM, Jones PA (1982) Mechanism of action of eukaryotic DNA methyltransferase. Use of 5-azacytosine-containing DNA. J Mol Biol 162: 679-692.
14. Zhang Y, Rohde C, Tierling S, Jurkowski TP, Bock C, et al. (2009) DNA methylation analysis of chromosome 21 gene promoters at single base pair and single allele resolution. PLoS Genet 5: e1000438.
15. Doerfler W (1983) DNA methylation and gene activity. Annu Rev Biochem 52: 93-124.
16. Jones PA (1985) Altering gene expression with 5-azacytidine. Cell 40: 485-486.
17. Egger G, Liang G, Aparicio A, Jones PA (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429: 457-463.
18. Lin KT, Momparler RL, Rivard GE (1981) High-performance liquid chromatographic analysis of chemical stability of 5-aza-2′-deoxycytidine. J Pharm Sci 70: 1228-1232.
19. Notari RE, DeYoung JL (1975) Kinetics and mechanisms of degradation of the antileukemic agent 5-azacytidine in aqueous solutions. J Pharm Sci 64: 1148-1157.
20. Jones PA, Taylor SM (1980) Cellular differentiation, cytidine analogs and DNA methylation. Cell 20: 85-93.
21. Osterman DG, DePillis GD, Wu JC, Matsuda A, Santi DV (1988) 5- Fluorocytosine in DNA is a mechanism-based inhibitor of HhaI methylase. Biochemistry 27: 5204-5210.
22. Friedman S, Ansari N (1992) Binding of the EcoRII methyltransferase to 5- fluorocytosine-containing DNA. Isolation of a bound peptide. Nucleic Acids Res 20: 3241-3248.
23. Kim CH, Marquez VE, Mao DT, Haines DR, McCormack JJ (1986) Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase. J Med Chem 29: 1374-1380.
24. Laliberte J, Marquez VE, Momparler RL (1992) Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2′-deoxycytidine by human cytidine deaminase. Cancer Chemother Pharmacol 30: 7-11.
25. Driscoll JS, Marquez VE, Plowman J, Liu PS, Kelley JA, et al. (1991) Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues. J Med Chem 34: 3280-3284.
26. Hurd PJ, Whitmarsh AJ, Baldwin GS, Kelly SM, Waltho JP, et al. (1999) Mechanism-based inhibition of C5-cytosine DNA methyltransferases by 2-H pyrimidinone. J Mol Biol 286: 389-401.
27. Taylor C, Ford K, Connolly BA, Hornby DP (1993) Determination of the order of substrate addition to MspI DNA methyltransferase using a novel mechanismbased inhibitor. Biochem J 291(Pt 2): 493-504.
28. Zhou L, Cheng X, Connolly BA, Dickman MJ, Hurd PJ, et al. (2002) Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol 321: 591-599.
29. Marquez VE, Eritja R, Kelley JA, Vanbemmel D, Christman JK (2003) Potent inhibition of HhaI DNA methylase by the aglycon of 2-(1H)-pyrimidinone riboside (zebularine) at the GCGC recognition domain. Ann N Y Acad Sci 1002: 154-164.
30. Stresemann C, Brueckner B, Musch T, Stopper H, Lyko F (2006) Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res 66: 2794-2800.
31. Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, et al. (2003) Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 95: 399-409.
32. Marquez VE, Kelley JA, Agbaria R, Ben-Kasus T, Cheng JC, et al. (2005) Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. Ann N Y Acad Sci 1058: 246-254.
33. Scott SA, Lakshimikuttysamma A, Sheridan DP, Sanche SE, Geyer CR, et al. (2007) Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression. Exp Hematol 35: 263-273.
34. Dote H, Cerna D, Burgan WE, Carter DJ, Cerra MA, et al. (2005) Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine. Clin Cancer Res 11: 4571-4579.
35. Balch C, Yan P, Craft T, Young S, Skalnik DG, et al. (2005) Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol Cancer Ther 4: 1505-1514.
36. Hellebrekers DM, Jair KW, Vire E, Eguchi S, Hoebers NT, et al. (2006) Angiostatic activity of DNA methyltransferase inhibitors. Mol Cancer Ther 5: 467-475.
37. Cheng JC, Weisenberger DJ, Gonzales FA, Liang G, Xu GL, et al. (2004) Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 24: 1270-1278.
38. Yoo CB, Chuang JC, Byun HM, Egger G, Yang AS, et al. (2008) Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev Res (Phila Pa) 1: 233-240.
39. Lemaire M, Momparler LF, Raynal NJ, Bernstein ML, Momparler RL (2009) Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2′-deoxycytidine. Cancer Chemother Pharmacol 63: 411-416.
40. Yoo CB, Cheng JC, Jones PA (2004) Zebularine: a new drug for epigenetic therapy. Biochem Soc Trans 32: 910-912.
41. Flotho C, Claus R, Batz C, Schneider M, Sandrock I, et al. (2009) The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia.
42. Suzuki M, Shinohara F, Endo M, Sugazaki M, Echigo S, et al. (2009) Zebularine suppresses the apoptotic potential of 5-fluorouracil via cAMP/PKA/CREB pathway against human oral squamous cell carcinoma cells. Cancer Chemother Pharmacol 64: 223-232.
43. Lee G, Wolff E, Miller JH (2004) Mutagenicity of the cytidine analog zebularine in Escherichia coli. DNA Repair (Amst) 3: 155-161.
44. van Bemmel DM, Brank AS, Eritja R, Marquez VE, Christman JK (2009) DNA (Cytosine-C5) methyltransferase inhibition by oligodeoxyribonucleotides containing 2-(1H)-pyrimidinone (zebularine aglycon) at the enzymatic target site. Biochem Pharmacol 78: 633-641.
45. O'Gara M, Klimasauskas S, Roberts RJ, Cheng X (1996) Enzymatic C5- cytosine methylation of DNA: mechanistic implications of new crystal structures for HhaL methyltransferase-DNA-AdoHcy complexes. J Mol Biol 261: 634-645.
46. Darii MV, Cherepanova NA, Subach OM, Kirsanova OV, Rasko T, et al. (2009) Mutational analysis of the CG recognizing DNA methyltransferase SssI: insight into enzyme-DNA interactions. Biochim Biophys Acta 1794: 1654-1662.
47. Shigdel UK, He C (2008) A new 1′-methylenedisulfide deoxyribose that forms an efficient cross-link to DNA cytosine-5 methyltransferase (DNMT). J Am Chem Soc 130: 17634-17635.
48. Jeltsch A (2006) On the enzymatic properties of Dnmt1: specificity, processivity, mechanism of linear diffusion and allosteric regulation of the enzyme. Epigenetics 1: 63-66.
49. Song L, James SR, Kazim L, Karpf AR (2005) Specific method for the determination of genomic DNA methylation by liquid chromatographyelectrospray ionization tandem mass spectrometry. Anal Chem 77: 504-510.
50. Yokochi T, Robertson KD (2002) Preferential methylation of unmethylated DNA by Mammalian de novo DNA methyltransferase Dnmt3a. J Biol Chem 277: 11735-11745.
51. Liu K, Wang YF, Cantemir C, Muller MT (2003) Endogenous assays of DNA methyltransferases: Evidence for differential activities of DNMT1, DNMT2, and DNMT3 in mammalian cells in vivo. Mol Cell Biol 23: 2709-2719.
52. Reither S, Li F, Gowher H, Jeltsch A (2003) Catalytic mechanism of DNA- (cytosine-C5)-methyltransferases revisited: covalent intermediate formation is not essential for methyl group transfer by the murine Dnmt3a enzyme. J Mol Biol 329: 675-684.
53. Mi S, Roberts RJ (1993) The DNA binding affinity of HhaI methylase is increased by a single amino acid substitution in the catalytic center. Nucleic Acids Res 21: 2459-2464.
54. Christman JK (2002) 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21: 5483-5495.
55. Reinisch KM, Chen L, Verdine GL, Lipscomb WN (1995) The crystal structure of HaeIII methyltransferase convalently complexed to DNA: an extrahelical cytosine and rearranged base pairing. Cell 82: 143-153.
56. Gowher H, Jeltsch A (2002) Molecular enzymology of the catalytic domains of the Dnmt3a and Dnmt3b DNA methyltransferases. J Biol Chem 277: 20409-20414.